PT  - JOURNAL ARTICLE
AU  - Madeleine D Burns
AU  - Yannic C Bartsch
AU  - Brittany P Boribong
AU  - Maggie Loiselle
AU  - Jameson P Davis
AU  - Rosiane Lima
AU  - Andrea G Edlow
AU  - Alessio Fasano
AU  - Galit Alter
AU  - Lael M Yonker
TI  - Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children
AID  - 10.1101/2022.01.05.22268617
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.05.22268617
4099  - http://medrxiv.org/content/early/2022/01/10/2022.01.05.22268617.short
4100  - http://medrxiv.org/content/early/2022/01/10/2022.01.05.22268617.full
AB  - What is already known on this topic?COVID-19 mRNA vaccine efficacy wanes over time in vaccinated adults; a third vaccine booster is now recommended for individuals over 16 years of age six-months after the two-vaccine series is completed.What is added by this report?We tested antibody durability of vaccine-induced full SARS-CoV-2 Spike and receptor binding domain (RBD) antibodies, as well as antibody levels specifically targeting the predominant variant of concern, Omicron, in younger adolescent children.What are the implications for public health practice?Waning anti-SARS-CoV-2 antibodies in adolescents support urgent authorization for a COVID-19 mRNA booster in the 12-15-year-old age group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Massachusetts General Hospital for Children, Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award, (MassCPR), the NIH, the Gates Foundation Global Health Vaccine Accelerator Platform funding (OPP1146996 and INV-001650), and the Musk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MGB IRB #2020P000955I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors